Abstract
Introduction
Resistance to antibiotics and antifungals represents a bigger threat than the financial crisis in 2008. Predicted estimations announce that 10,000,000 people can die due to this phenomenon with major impact for demography, economics (10 trillion USD), and healthcare [1] . There is a worldwide scientific dedication to analyze epidemiological data for each country, area, hospital, and department in order to control this phenomenon known as 'antifungal or antibiotic stewardship'. Especially in IFI, where the late and low identification rates of invasive fungal infections (IFI) in blood cultures, debatable specificity and sensibility of biomarkers and the high mortality of these infections, determined medical practitioners to administrate the empirical therapy along with prophylactic usage on patients at risk. This overuse of empirically and prophylactic treatments generate resistance and species distribution changes. The most common fungal infections of hospitalized patients are invasive candidiasis. Of all Candida species, 15 are involved in pathogenicity. Around 90% of invasive infections are determined by C. albicans, C. glabrata, C. tropicalis,C. parapsilosis, and C. krusei [2] with a shift from C.albicans in favor of non-albicans in recent years, due to high presence in intensive care patients predicted to be between 0.5 and 10% [3] . The lowest presence is in patients with neoplasm and transplant of hematopoietic stem cells from 0.15% to 1.55% [4] . Some antifungals do not have efficiency against some species, such as C.krusei to fluconazole. Globally, researchers are facing a risk of 33% high resistance to fluconazole and also to echinocandins (for example anidulafungin, percentage of resistance is close to 6.4%) [5] . C.glabrata has a high potential of resistance to echinocandins and was detected predominantly in the bloodstream of patients with infections associated with healthcare (HAI). Resistance was detected in a percentage of 5.1% for caspofungin, 3.8% to anidulafungin, 3.2% to micafungin, 7.7% for fluconazole, 5.1% for posaconazole, and 6.4% for voriconazole [6] . In Romania, clear evaluations regarding susceptibility are limited, excepting one multicenter study regarding susceptibility pattern of 551 species from bloodstream (BSI), superficial and deep-seated fungal infections which identified a resistance of 10.2% to fluconazole and 2.5% to voriconazole globally, and 4% in BSI [7] . This constituted the rationale to develop an analysis of antifungal susceptibilities in Romania for IFI. In order to identify susceptibility to antifungals we can use options such as automatic systems (VITEK 2 C®) or visual identifications compared with a scale like YEA-STONE®, E-TEST®. Vitek 2 C® represents an automatic system of identification of germs and susceptibility offering the "breakpoints" associated with minimum inhibitory concentration (MIC). Studies showed that IFI with C. albicans having a value of MIC over 2 mg/L had a high rate of mortality. This means that it is important to see the level for our isolates in each center [8] .
Material and method
In order to evaluate the susceptibility of antifungals and options for antifungal agents we retrospectively analyzed all the isolates on fungal bloodstream infections (BSI), catheter colonization and cerebrospinal fluid infections detected by VITEK 2 assessed at the microbiology laboratory in the National Institute for Infectious Plates, 2015) [9] . As reference strain C. parapsilosis ATCC 22019 was used. The option was for SYO, YO10 type due to its structure of antifungals present on the Romanian pharmaceutical market (excepting Amphotericin B and 5-Flucytozine). Plate inoculation was done accordingly to the manufacturer's instructions. The interpretation was done visually. We identified within the microbiology lab files the susceptibility to antifungals offered by VITEK2® and compared to YEASTONE ® in order to track errors (minor, major, very major error).
Results
We evaluated 79 isolates identified in proven IFI and only 15 isolates were recovered after passing on Sabouraud medium from the 2010-2016 collection bank. The rate of incidence of IFI was evaluated at 3.7 on 1,000 hospitalized patients. Regarding epidemiological descriptive data, this study evaluated age, gender, HIV status. The age in this study (medium age) was 41 years and the extreme ages were 12 years old and 83 years old. Male gender was predominant with 59%. Most of the patients came from from urban areas. The rate of HIV infection in this IFI study group was 27%.
In the present study 15 isolates grown on Sabouraud, transferred on YEASTONE® YO10-MIC's were incubated at 35°C and the results were visually read after the legend provided by the producer. All the selected samples had a positive control marker. Regarding the accuracy of the method, no errors were noticed.
The comparison of the values of MIC's of the same isolates obtained on YEASTONE and MIC´s obtained by automated system VITEK2C® (breakpoints) are presented in tables I and table II.
The range of MIC's on YEASTONE® YO10 varied as follows: fluconazole between ≤ 0.06 mcg/ml and 0.25 mcg/ml, voriconazole ≤ 0.008 mcg/ml and 0.25 mcg/ml, posaconazole 0.015 mcg/ml and 1 mcg/ml, itraconazole ≤ 0.015 mcg/ml and 0.50 mcg/ml, caspofungin between 0.015 mcg/ml and 0.50 mcg/ml, anidulafungin 0.015 mg/ml and 2 mg/ml, micafungin ≤ 0.008mcg/ml and 2 mcg/ml, amphotericin B between ≤ 0.12 mcg/ml and 0.5 mcg/ml, 5 -flucytozine 0.25 mcg/ml to 8 mcg/ml.
The range of MIC's identified on VITEK2® (breakpoints) varied as follows: fluconazole between ≤ 1 mcg/ml and 2 mcg/ml, voriconazole ≤ 0.12 mcg/ml, caspofungin between ≤ 0.25 mcg/ml and 1 mcg/ml, micafungin ≤ 0.06 mcg/ ml and 0.50 mcg/ml, amphotericin B between ≤ 0.25 mcg/ml and 1 mcg/ml. This present study compared the MIC from tables I and II generated by YEASTONE® with EUCAST standards (8.0 version, November 2015) and versus CLSI standards (2012 version) and obtained -S -susceptible, I -intermediary, R -resistant.
The susceptibilities were compared in table  III, table IV and table V voriconazole, echinocandins (caspofungin and anidulafungin) were de-escaladed based on the susceptibility to antifungals generated by VITEK2C® in 37% of cases.
Discussions
Regarding identifications of isolates and the study importance, being a retrospective study, one of the limitations revolves around the low T -total number of species ; S -number of species with susceptibility ; I -number of species with intermediary susceptibility; R -number of species with resistance to antifungals.
For C. kefyr, C. lusitaniae, C. dubliniensis it has been no data on EUCAST and CLSI. T -total number of species; S -number of species with susceptibility; I -number of species with intermediary susceptibility; R -number of species with resistance to antifungals.
For C.kefyr, C.lusitaniae ,C. dubliniensis -no data on EUCAST and CLSI were available to compare.
number of isolates tested on micro broth dilutions (only 15) in comparison with 79 obtained from sterile sites on Vitek2C®, namely that some did not cultivate after passing form bank to Sabouraud agar. Another limitation is that some species of Candida were not identified on VITEK 2C®(5.45%). VITEK system can cause errors -for example 4 cases (8 isolates from blood cultures) of C.auris, first cases identified in Europe, a species alerted via CDC alerting system, resistant to fluconazole and voriconazole, with susceptibility conserved to posaconazole, itraconazole, echinocandines și amphotericin B identified using ITS rDNA was considered by VITEK technology as C.lusitaniae, C.haemulonii while 6 isolates remained unidentified [10] . Using ITS "internal transcribed spacer" of ribosomal DNA some species identified on VITEK can be reconsidered and those unidentified can be precisely identified as Merseguel et al. identified 300 species in IFI [11] . It is possible that some isolates be misidentified as literature presents. For susceptibility data, some studies identified differences between MIC's versus Clinical and Laboratory Standards (CLSI) breakpoints established in 2012 -96.5% in C. albicans, 85.8% in C. tropicalis and 92.1% in C.parapsilosis according to the revised CBP's fluconazole susceptibility [12] . Sensititre YEASTONE compared with CLSI standards modified in 2012 regarding susceptibility to echinocandins generated only 1% errors [13] . Sensititre YEASTONE a microbroth dilution method used in clinical practice [14] obtained values of susceptibility in percentages of 98.7% in C. albicans, 92.5% in C.glabrata 92.3% in the C. parapsilosis complex, 96.1% in C. tropicalis ,and 100% in C. Guillermondii [15] for voriconazole and fluconazole this proving the accuracy of the method. Vijgen et al. identified in 2011 a concordance of 78.4%, 84.6% and 90.8% for fluconazole, voriconazole and amphotericin B between Vitek 2 and Sensititre YeastOne (SYO) [16] . Farina et al. in 2011 , in a cooperation microbiology project which evaluated susceptibilities of 70 isolates of Candida on VITEK2 System and Sensititre YeastOne® to amphotericin B, voriconazol, fluconazol, flucytosine showed the results which credited VITEK system with a concordance for amphotericin B, fluconazole, voriconazole and 5-flucytozine (from 81.4% to 88.6%).The researchers recommend VITEK with the mention to readjust the breakpoints [17] .
In the present study, obtaining the MICs of Candida spp. was essential for epidemiological data and the errors between VITEK® MIC's and MIC's obtained by YEASTONE with 0 errors were crucial for clinicians' confidence and also for understanding the limits of the actual systems and potential of new technologies.
YEASTONE is correlated 100% with VITEK2® in terms of susceptibility. No antifungal resistance acquired events were reported in comparison with one study from Italy also using the YEASTONE panel where the fluconazole resistance on Candida spp. decreases to 5.4% in 2016 from 24.9% in a survey from 2009 [18] . Because no resistance to fluconazole was noticed in the susceptibility data we consider that first choice of fluconazole in medical practice the proper option when candidemia is suspected even if guidelines recommend echinocandins for candidemia [2, 19] . Susceptibility to azoles, echinocandins, and amphotericin B in Romanian species involved in infectious diseases IFI is preserved in comparison with a 6 years' analysis in Switzerland (FUNGINOS project) where resistant isolates were mentioned [20] .
Conclusions
The incidence in proven candidemia was 3.7 on 1,000 hospitalized patients. In these IFI patients, HIV infection was present in 27% of patients, predominantly males from urban areas with age limits between 12-83 years old. All our YEASTONE susceptibility determined data (S -susceptible, I-intermediary, R-resistant) corresponded 100% to VITEK2® technology with no antifungal acquired resistance even on identification VITEK had some limitations. No resistance to any antifungal was noticed. Proportionally, the first option of treatment was fluconazole, followed by voriconazole and caspofungin, anidulafungin.
